EMEA Life Sciences Industry & Cluster Report 2026

The GCC (Cooperation Council for the Arab States of the Gulf) pharmaceutical market topped $30B in 2025, with biotech investment exceeding $12B over the past five years, signalling a fundamental transformation in the region's approach to life sciences.

Recent global and regional crises have catalysed a strategic shift, elevating healthcare self-sufficiency from a long-term vision to a pressing national security imperative. The COVID-19 pandemic exposed extreme vulnerabilities in global pharmaceutical supply chains, whilst regional conflicts disrupting maritime trade amplified the economic and security risks of import reliance.

Governments are now deploying accelerated, large-scale investment to build robust domestic production capabilities. Saudi Vision 2030 and the UAE's AED 300B 'Operation 300B' are channelling billions into R&D hubs and advanced manufacturing, whilst generics are set to reach $14.7B by 2032 and biosimilars grow at 15–20% annually.

Specialised clusters are emerging across the region—from Riyadh and Dubai as integrated leaders to Abu Dhabi and Doha as research specialists—creating compelling real estate opportunities in laboratory, manufacturing, and cold-chain logistics infrastructure. Yet significant gaps remain in large-scale clinical trial capacity, presenting substantial near-term investment potential.

The GCC life sciences landscape is characterized by distinct cluster specializations, each playing a strategic role in the region's path to self-sufficiency.